Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

GI Skin: Cutaneous Manifestations of Gastrointestinal Disease

Description

In this session on cutaneous manifestations of gastrointestinal diseases, Dr. Alexander Coramilis and Dr. Stephanie Gallatano explore the correlation between skin and GI disorders, focusing on conditions such as celiac disease and inflammatory bowel disease (IBD). They aim to educate attendees on recognizing and diagnosing skin symptoms linked to GI issues, initiating evaluations based on these presentations, and collaborating with multidisciplinary teams for comprehensive patient care. The discussion includes dermatitis herpetiformis related to celiac disease, which can manifest diversely on the skin, necessitating treatments like a gluten-free diet and medications such as dapsone. They also delve into the systemic effects of IBD, noting that up to 40% of patients experience skin manifestations, often requiring specific dermatologic treatment. Clinicians are urged to assess for Crohn's disease and ulcerative colitis through detailed patient histories and appropriate laboratory evaluations. In addition to traditional therapies, the talk highlights emerging treatments, including biologics and Jak inhibitors, thus enhancing the management of skin conditions related to GI diseases. The session ends with a call to action for dermatologists to recognize these cutaneous signs effectively, thereby playing a crucial role in the timely diagnosis and treatment of underlying inflammatory bowel diseases.

View more

Conclusions

  • Dermatologists play a crucial role in identifying cutaneous manifestations as indicators of underlying gastrointestinal diseases such as inflammatory bowel disease (IBD) and celiac disease.
  • Cutaneous manifestations can present at any stage of gastrointestinal disease and may require specialized dermatologic treatment.
  • Multidisciplinary collaboration is essential for effectively managing gastrointestinal inflammatory conditions and their associated cutaneous manifestations.
  • Emerging therapies, including biologic treatments and new immunosuppressants, show promise in improving outcomes for patients with cutaneous IBD and celiac disease.
  • Patients presenting with specific cutaneous symptoms should be evaluated for potential underlying gastrointestinal issues to ensure timely diagnosis and treatment.
  • N Engl J Med 2007; 356:2547. DOI: 10.1056/NEJMc070200
  • Jared S Kahn1, Katherine Moody2 MD, David Rosmarin1,2 MD. International Journal of Dermatology, Volume 27 Number 7| July 2021, 27(7):6.
  • Oral Crohn's Disease. J Oral Maxillofac Pathol. 2014; Clin Gastroenterol Hepatol. 18(1): S139-42.
  • Inflamm Bowel Dis. 2016;22(5):1071-7. Dermatology. 2021;237(4):635-640. J Crohns Colitis. 2012 Mar;6(2):135-42.
  • Clin Colon Rectal Surg. 2007 Nov;20(4):282-93. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1113-20. N Engl J Med. 2004 Feb 26;350(9):876-85.
  • J Am Acad Dermatol. 2014;71:804-13. Pediatr Dermatol. 2018; 35(5): 566-74. J Crohns Colitis. 2015 Apr;9(4):318-25.
  • J Cutan Pathol. 2021 Apr;48(4):465-468.
  • Am Acad Dermatol. 2014; 71(4): 804-813. J Gastroenterol Hepatol. 2018; 33(12):1969-1974. ACG Case Rep J. 2020;1 7(8): e00452. Cureus. 2021; 13(7): e16252.
  • Risankizumab as induction therapy for Crohn's disease: The NEW ENGLAND JOURNAL of MEDICINE
  • Lancet 2022; 399:2113-28. Published Online May 26, 2022. doi:10.1016/
  • Front Immunol. 2022 Sep 29;13:1013900. JAMA Dermatol. 2020 Mar 1;156(3):335. N Engl J Med. 2021 Nov 25;385(22):e77.
  • Autoimmunity. 2012 Feb;45(1):91-101. Expert Opin Pharmacother. 2011 Jun;12(8):1259-68. J Dtsch Dermatol Ges. 2023 Jul;21(7):779-784.